The role of P2Y6 receptor in the pathogenesis of cardiovascular and inflammatory diseases

IF 3 3区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of pharmacological sciences Pub Date : 2024-01-05 DOI:10.1016/j.jphs.2024.01.003

Kazuhiro Nishiyama

{"title":"The role of P2Y6 receptor in the pathogenesis of cardiovascular and inflammatory diseases","authors":"Kazuhiro Nishiyama","doi":"10.1016/j.jphs.2024.01.003","DOIUrl":null,"url":null,"abstract":"<div>The purinergic receptor P2Y6 receptor (P2Y6R) is a member of the G protein-coupled receptors (GPCR) family. P2Y6R is widely expressed in various cell types and plays a critical role in physiological processes, where it is activated by extracellular uridine diphosphate (UDP) and mobilizes Ca2+ via the Gαq/11 protein pathway. We have recently discovered the pathophysiological role of P2Y6R in cardiovascular and inflammatory diseases, including inflammatory bowel disease and non-alcoholic fatty liver disease. Furthermore, we uncovered the redox-dependent internalization of P2Y6R. In this review, we provide a comprehensive overview of the pathophysiological activity of P2Y6R in cardiovascular and inflammatory diseases. Additionally, we discuss the concept of atypical internalization control of GPCRs, which may be applied in the prevention and treatment of intestinal inflammation and cardiovascular remodeling.</div>","PeriodicalId":16786,"journal":{"name":"Journal of pharmacological sciences","volume":"154 2","pages":"Pages 108-112"},"PeriodicalIF":3.0000,"publicationDate":"2024-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1347861324000033/pdfft?md5=247fd27157e9f44c7eecbc02e15a9785&pid=1-s2.0-S1347861324000033-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmacological sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1347861324000033","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

The purinergic receptor P2Y₆ receptor (P2Y₆R) is a member of the G protein-coupled receptors (GPCR) family. P2Y₆R is widely expressed in various cell types and plays a critical role in physiological processes, where it is activated by extracellular uridine diphosphate (UDP) and mobilizes Ca²⁺ via the G_αq/11 protein pathway. We have recently discovered the pathophysiological role of P2Y₆R in cardiovascular and inflammatory diseases, including inflammatory bowel disease and non-alcoholic fatty liver disease. Furthermore, we uncovered the redox-dependent internalization of P2Y₆R. In this review, we provide a comprehensive overview of the pathophysiological activity of P2Y₆R in cardiovascular and inflammatory diseases. Additionally, we discuss the concept of atypical internalization control of GPCRs, which may be applied in the prevention and treatment of intestinal inflammation and cardiovascular remodeling.

查看原文本刊更多论文

P2Y6 受体在心血管疾病和炎症性疾病发病机制中的作用

嘌呤能受体 P2Y6 受体（P2Y6R）是 G 蛋白偶联受体（GPCR）家族的成员。P2Y6R 广泛表达于各种细胞类型，在生理过程中发挥着关键作用，它被细胞外的二磷酸尿苷（UDP）激活，并通过 Gαq/11 蛋白途径调动 Ca2+。我们最近发现了 P2Y6R 在心血管和炎症性疾病（包括炎症性肠病和非酒精性脂肪肝）中的病理生理作用。此外，我们还发现了 P2Y6R 的氧化还原依赖性内化。在这篇综述中，我们全面概述了 P2Y6R 在心血管和炎症性疾病中的病理生理活性。此外，我们还讨论了 GPCR 非典型内化控制的概念，该概念可应用于肠道炎症和心血管重塑的预防和治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of pharmacological sciences 医学-药学

CiteScore

6.20

自引率

2.90%

发文量

104

审稿时长

31 days

期刊介绍： Journal of Pharmacological Sciences (JPS) is an international open access journal intended for the advancement of pharmacological sciences in the world. The Journal welcomes submissions in all fields of experimental and clinical pharmacology, including neuroscience, and biochemical, cellular, and molecular pharmacology for publication as Reviews, Full Papers or Short Communications. Short Communications are short research article intended to provide novel and exciting pharmacological findings. Manuscripts concerning descriptive case reports, pharmacokinetic and pharmacodynamic studies without pharmacological mechanism and dose-response determinations are not acceptable and will be rejected without peer review. The ethnopharmacological studies are also out of the scope of this journal. Furthermore, JPS does not publish work on the actions of biological extracts unknown chemical composition.